Because of the lack of available treatments, studies combining non-clear and clear cell carcinomas have focused on angiogenesis inhibitors (anti-VEGF) and other targeted therapies (mTOR inhibitors). This evidence concerns the gene VEGFA and clear cell adenocarcinoma.